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In this issue of Cell Stem Cell, Wang et al. (2014) describe a signaling axis present in bone marrow stromal
cells that suppresses inflammation and myeloid expansions. Loss of endothelial Notch signaling leads
to deregulation ofmiR-155 expression, activation of NF-kB, and increased proinflammatory cytokine produc-
tion, which promotes a myeloproliferative phenotype.Notch signaling in the bone marrow
microenvironment is critical for the main-
tenance of hematopoiesis (Weber and
Calvi, 2010). Upon ligand binding, Notch
is activated and cleaved, leading to the
release of the Notch intracellular domain
(NICD) and its translocation to the nucleus
where it represses or activates down-
stream target genes upon binding to a
member of the CSL family of transcription
factors (RBPJ in mice) (Sandy and Mail-
lard, 2009). Conditional knockout mouse
models deleting different components of
this pathway have established the critical
importance of stromal Notch signaling:
deregulated Notch signaling leads to
abnormal lymphoid and myeloid hemato-
poiesis, including myeloproliferative phe-
notypes (Kim et al., 2008; Yao et al.,
2011; Yoda et al., 2011). However, the
specific mechanisms accounting for
these phenotypes have remained unclear
Since the prior studies concluded that
Notch regulates hematopoietic mainte-
nance in a cell-autonomous manner,
a nonautonomous manner, or both,
depending on the specific gene investi-
gated. One likely explanation for these
discrepancies is that the genes investi-
gated did not exclusively regulate Notch
signaling, emphasizing the need for the
generation of a mouse model lacking
Notch signaling solely. In this issue of
Cell Stem Cell, Wang et al. (2014) demon-
strate that deletion of a highly specific
component of Notch signaling, RBPJ, in
stromal endothelial cells (ECs) is sufficient
to drive a phenotype resembling human
myeloproliferative disease.
In this study, Wang et al. showed that
while transplantation of RBPJ/ bonemarrow cells into WT recipients resulted
only in minor effects on hematopoiesis,
the reciprocal experiment led to a severe
myeloproliferative phenotype. To deter-
mine the molecular mechanisms underly-
ing this dramatic phenotype, the authors
measured cytokines in the serum of
RBPJ/ mice and found a significant
increase in levels of G-CSF. G-CSF was
a critical mediator of the RBPJ/ pheno-
type, because antibody-mediated neu-
tralization of G-CSF reversed the myelo-
proliferative phenotype, suggesting that
the RBPJ loss induces a proinflammatory
environment. This intriguing finding iden-
tifies Notch as a negative regulator of
inflammation in the bone marrow micro-
environment. Taking advantage of a
Tie2-Cre RBPJfl/fl model, the authors
showed that specific loss of RBPJ in
ECs is sufficient to induce most of the
phenotypic alterations observed in the
RBPJ/ mutants. In addition, using a
combination of biochemical and func-
tional assays, they showed that miR-
155 is directly repressed by RBPJ, and
that miR-155 induction upon loss of
RBPJ is sufficient to induce G-CSF
expression in stromal cells, linking defec-
tive Notch signaling in the niche to acti-
vation of an miRNA. The authors then
identified kB-Ras1, a negative regulator
of NF-kB, as the target gene mediating
the miR-155 effect. Together, these
data demonstrate that loss of Notch
signaling in ECs leads to increased
inflammation as a result of miR-155-
mediated activation of NF-kB, leading
to a G-CSF-mediated myeloproliferation
(Figure 1). In doing so, this signaling
axis provides further support for a modelCell Stemlinking inflammation and cancer (Tili
et al., 2009).
Previous studies have shown that
miR-155 likely plays a role in the patho-
genesis of myeloid disorders in a
hematopoietic cell-autonomous manner
since ectopic expression of miR-155 in
hematopoietic stem/progenitor cells is
sufficient to induce a myeloproliferative-
like disorder (O’Connell et al., 2008). In
contrast, these findings by Wang et al.
support a stromal role for miR-155
in myeloid disease pathogenesis. The
inability of RBPJ/ bone marrow cells
to exhibit a myeloproliferative phenotype
might be explained by the degree of
miR-155 induction in the two studies, as
miR-155 was induced only 2-3-fold in
RBPJ/ cells while enforced expression
of miR-155 associated with a myeloprolif-
erative phenotype was 30-fold, suggest-
ing a dose-dependent effect of miR-155
on hematopoietic cells. Future experi-
ments measuring miR-155 expression in
HSPCs and stromal cells from patients
with myeloproliferative disease should
help to clarify whether the miR-155
effect is predominantly a hematopoietic
or stromal contribution.
Overall, these studies expand the
growing list of alterations in the bone
marrow microenvironment that are suffi-
cient to induce robust hematologic
phenotypes. Other groups have also
demonstrated that genetically altered
stromal cells can induce phenotypes
mimicking human hematologic disorders
including acute leukemias (Wnt/b-catenin;
Kode et al., 2014 as well as myelodyspla-
sias followed by leukemia (e.g. Dicer;
Raaijmakers et al., 2010). These findingsCell 15, July 3, 2014 ª2014 Elsevier Inc. 1
Figure 1. Proposed Model for Notch-Mediated Contributions to
Myeloid Disease Pathogenesis
Endothelial cells in the bone marrow normally transduce Notch ligand-depen-
dent signals. Decreased stromal Notch signaling though loss of RPBJ causes
induction of proinflammatory cytokines such as G-CSF, and consequently, a
myeloproliferation. Similar mechanisms may be present in human myelopro-
liferative disorders, but this remains an open question. Red arrows depict
the consequences of reduced Notch signaling in stromal endothelial cells.
Factors that may contribute to reduced Notch signaling in the stroma in the
context of human disease are not well understood, but stromal-niche-cell-
intrinsic or -extrinsic factors may contribute to the downregulation of this
pathway.
Cell Stem Cell
Previewsraise a number of questions
regarding the mechanism of
Notch regulation in the niche.
One interesting next step
would be to identify the up-
stream factors that cause
reduced stromal Notch sig-
naling. One might speculate
that the stroma is educated
by the hematopoietic com-
partment itself to decrease
Notch signaling, and such
changes may be initiated by
the genetically altered he-
matopoietic cells present in
patients with myeloprolifera-
tive disorders. Another fasci-
nating possibility is that sup-
pression of stromal Notch
signaling occurs independent
of the hematopoietic com-
partment through systemic
factors produced by nonhe-
matopoietic cell types or
even by genetic/epigenetic al-
terations in the Notch/RBPJ
signaling components in the
stromal cells themselves.
Future work focusing on char-
acterizing the genetic, tran-scriptional, and proteomic status of stro-
mal components isolated from patients
with myeloid diseases could directly
address this issue and potentially provide
novel therapeutic targets.
Finally, these studies suggest a number
of potential therapeutic strategies that
may be employed in patients with myelo-
proliferative disorders including selective
Notch agonists affecting the Notch/
RBPJ axis, G-CSF antagonists, miR-155
antagonists, and NF-kB inhibitors. How-2 Cell Stem Cell 15, July 3, 2014 ª2014 Elsevever, prolonged use of these treatments
in patientsmight adversely affect hemato-
poiesis, because many of these pathways
regulate normal HSC function. Future
targeted therapeutic strategies will need
to verify the ability of these therapies to
mitigate disease and their ability to target
disease stem cells. Moreover, because
Notch signaling pathway inhibition is likely
to affect both hematopoietic and stromal
cells in the bone marrow, it will be impor-
tant to determine whether therapeuticier Inc.effects are due to their spe-
cific actions on either of these
cellular compartments.
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